APTENSIO XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aptensio Xr, and when can generic versions of Aptensio Xr launch?
Aptensio Xr is a drug marketed by Rhodes Pharms and is included in one NDA.
The generic ingredient in APTENSIO XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aptensio Xr
A generic version of APTENSIO XR was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
Summary for APTENSIO XR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 62 |
Clinical Trials: | 4 |
Patent Applications: | 3,514 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for APTENSIO XR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for APTENSIO XR |
What excipients (inactive ingredients) are in APTENSIO XR? | APTENSIO XR excipients list |
DailyMed Link: | APTENSIO XR at DailyMed |
Recent Clinical Trials for APTENSIO XR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Matthew O'Brien | Phase 4 |
Matthew J O'Brien, PhD, BCBA-D | Phase 4 |
Rhodes Pharmaceuticals, L.P. | Phase 4 |
Pharmacology for APTENSIO XR
Drug Class | Central Nervous System Stimulant |
Physiological Effect | Central Nervous System Stimulation |
Anatomical Therapeutic Chemical (ATC) Classes for APTENSIO XR
Paragraph IV (Patent) Challenges for APTENSIO XR
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
APTENSIO XR | Extended-release Capsules | methylphenidate hydrochloride | 30 mg | 205831 | 1 | 2016-03-28 |
APTENSIO XR | Extended-release Capsules | methylphenidate hydrochloride | 15 mg, 20 mg, 40 mg and 50 mg | 205831 | 1 | 2015-12-28 |
APTENSIO XR | Extended-release Capsules | methylphenidate hydrochloride | 10 mg | 205831 | 1 | 2015-12-24 |
APTENSIO XR | Extended-release Capsules | methylphenidate hydrochloride | 60 mg | 205831 | 1 | 2015-12-23 |
US Patents and Regulatory Information for APTENSIO XR
Expired US Patents for APTENSIO XR
International Patents for APTENSIO XR
See the table below for patents covering APTENSIO XR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2224740 | ⤷ Try a Trial | |
European Patent Office | 1143937 | FORMULATIONS A LIBERATION CONTROLEE CARACTERISEES PAR UNE ACTION IMMEDIATE ET UNE DIMINUTION RAPIDE DES CONCENTRATIONS EFFICACES DE MEDICAMENTS DANS LE PLASMA (CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS) | ⤷ Try a Trial |
Japan | 2002532410 | ⤷ Try a Trial | |
Spain | 2306535 | ⤷ Try a Trial | |
Lithuania | 1967191 | ⤷ Try a Trial | |
Denmark | 1140088 | ⤷ Try a Trial | |
Australia | 2122700 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |